Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on May 24, 2019. The filing addresses an extension of the expiration date for Exchange Offers and Consent Solicitations related to notes issued by Celgene Corporation, which are part of Bristol-Myers Squibb's planned acquisition of Celgene (the "Merger").
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figure disclosed relates to the debt exchange program:
- Aggregate Principal Amount of New Notes: Up to $19,850,000,000.
Material Changes
The primary material change reported is the extension of the expiration date for the Exchange Offers and Consent Solicitations regarding Celgene Notes:
- Previous Expiration Date: June 3, 2019, at 5:00 p.m. New York City time.
- New Expiration Date: July 8, 2019, at 5:00 p.m. New York City time.
- Reason for Change: The extension aligns with the expected closing of the Merger, which is anticipated to occur in the third quarter of 2019.
Outlook, Risks, and Management Commentary
Merger Timeline and Conditions:
- The Exchange Offers and Consent Solicitations are conditioned upon the closing of the Merger, a condition that cannot be waived by Bristol-Myers Squibb.
- The settlement of the offers is expected to occur promptly after the Expiration Date and on or about the Merger closing date.
- Management notes that the Expiration Date may be further extended one or more times if necessary, with advance notice provided.
Legal and Structural Updates:
- Supplemental indentures to eliminate restrictive covenants and certain events of default in the Celgene Notes were executed on May 1, 2019, but will only become operative upon the settlement of the Exchange Offers.
Investor Verification Checklist
- Verify the final closing date of the Bristol-Myers Squibb and Celgene Merger to confirm if the July 8, 2019, expiration date requires further extension.
- Confirm the total volume of Celgene Notes tendered in the Exchange Offers against the $19.85 billion aggregate principal amount limit.
- Review the definitive terms of the new notes issued by Bristol-Myers Squibb to replace the Celgene Notes.
- Monitor for any additional 8-K filings regarding further extensions of the Expiration Date.